Shares of CEL-SCI are up $2.48, or 75%, to $5.78 in midday trading after STAT News’ Adam Feuerstein reported before the open that the company’s CEO, Geert Kersten, held an invitation-only conference call last Wednesday and tipped off a select group of investors and brokers about plans to issue a “major press release” later this week, possibly on Thursday, related to cancer drug Multikine. The private call could get Kersten and Cel-Sci in “trouble with federal regulators,” Feuerstein added in his report earlier.
previous post